RBC Capital analyst Conor McNamara maintained a Hold rating on Hologic (HOLX – Research Report) on February 2 and set a price target of $76.00. The company’s shares closed yesterday at $72.04.
McNamara covers the Healthcare sector, focusing on stocks such as Hologic, Illumina, and SOPHiA GENETICS. According to TipRanks, McNamara has an average return of -8.2% and a 45.33% success rate on recommended stocks.
In addition to RBC Capital, Hologic also received a Hold from Morgan Stanley’s Tejas Savant in a report issued on February 3. However, on February 2, Needham reiterated a Buy rating on Hologic (NASDAQ: HOLX).
See the top stocks recommended by analysts >>
HOLX market cap is currently $17B and has a P/E ratio of 34.44.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HOLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hologic (HOLX) Company Description:
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.
Read More on HOLX:
- Hologic price target raised to $84 from $82 at Morgan Stanley
- Hologic price target raised to $90 from $83 at Needham
- Hologic price target raised to $79 from $78 at UBS
- Hologic’s Genius Digital Diagnostics System cleared by FDA
- Hologic raises FY24 EPS view to $3.97-$4.12 from $3.90-$4.10, consensus $4.00
